Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 21, 2020; 26(43): 6770-6781
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6770
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6770
Ref. | Type of study | Patient (n) and characteristics | Follow-up time | Recurrent HCC incidence |
Reig et al[13] | Retrospective study | DAA-treated (n = 103) | Mean FU: 5.7 mo | 27.6% |
Conti et al[14] | Retrospective study | DAA-treated (n = 59) | Mean FU: 5.6 mo | 28.8% |
ANRS CO22 HEPATHER[64] | Prospective study | DAA-treated (n = 189), untreated (n = 78) | Mean FU: 20.2 mo | 0.73 per 100 person-months |
ANRS CO12 CirVir[64] | Prospective study | All biopsy proven cirrhotic patients, DAA-treated (n = 13), untreated (n = 66) | Median FU: 21.3 mo (IQR: 13.0-33.5) | 1.11 per 100 person-months |
ANRS CO23 CUPILT[64] | Prospective study | LT recipients for HCC, treated with DAA (n = 314) | Mean FU: 70 ± 64 mo after LT | 2.2% |
Cabibbo et al[65] | Prospective study | DAA-treated (n = 143) | Mean FU: 8.7 mo | 20.3% |
Lin et al[59] | Retrospective study | DAA-treated (n = 60), untreated (n = 47) | Median FU: 20 mo | 37.1% |
Singal et al[60] | Retrospectivestudy | DAA-treated (n = 304), IFN-treated (n = 489) | Median FU: 10.4 mo (IQR: 5.3-20.8) since complete remission | DAA treated 42.1%, untreated 52.9% |
Nagata et al[62] | Retrospectivestudy | DAA-treated (n = 83), IFN-treated (n = 60) | Mean FU: IFN 81.6 mo, DAA 21.6 mo | IFN-treated 54.2%, DAA- treated 45.1% |
Imai et al[63] | Retrospective study | DAA-treated (n = 13), IFN-treated (n = 34), untreated (n = 70) | N/A |
- Citation: Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781
- URL: https://www.wjgnet.com/1007-9327/full/v26/i43/6770.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i43.6770